Traceability system: unique as a person’s fingerprint

The widespread adoption of global serialization and traceability mandates to ensure product integrity and protect patient safety is driving unprecedented changes in the pharmaceutical industry. The evolution and investment associated with product serialization have been significant.

The critical challenge for the industry is, how to deliver a Return on Investment through operational benefits for their organization, considering these additional costs for regulatory compliance.

Stevanato Group understands this need and has created a solution for the traceability of primary containers, which can add significant value for pharma companies, enabling them to deliver a measurable return on their existing investments.

In the same way that secondary packaging has a unique identity, Stevanato Group has developed a process that replicates this process for any primary glass container for parenteral medicines. All glass syringes, cartridges, and vials will be printed with a unique machine-readable code; which is as individual as a person’s fingerprint.  This unique identity delivers an extensive range of internal and external benefits.

Following extensive research with Stevanato Group customers, the following key business case metrics have been defined:

To simplify implementation and validation, the solution has been designed and tested to be:

 

To encourage industry adoption, Stevanato Group is actively engaged with a consortium of large pharma organizations and external third parties, to facilitate the creation of a standard that can be applied and utilized to ensure commonality across different vendors.

04.06.2019, STEVANATO GROUP

News material on the Site is copyright and belongs to the Company or to its third party news provider, and all rights are reserved. Any User who accesses such material may do so only for its own personal use, and the use of such material is at the sole risk of the User. Redistribution or other commercial exploitation of such news material is expressly prohibited. Where such news material is provided by a third party, each User agrees to observe and be bound by the specific terms of use applying to such news material. We do not represent or endorse the accuracy or reliability of any of the info contained in any news or external websites referred to in the news.

Should the content or the design of these sites violate third parties rights or legal prescriptions, we kindly ask you to send us a respective message without invoice or cost. We guarantee that passages where the claim is considered as justified will be removed immediately, without any necessity to involve any lawyer into this issue. We will reject any claim caused by submission of a honorary note in this regard without any prior contact and confirmation of the issueby us and we reserve the right ssue counter claim ourselves because of violation of aforesaid conditions.